Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)

Anbio Biotechnology has reported Common Equity for 3 years, with the latest figure at $30.2 million in Q4 2025.

• On a quarterly basis, Common Equity rose 75.41% year-over-year to $30.2 million in Q4 2025; TTM through Dec 2025 was $30.2 million, a 75.41% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 75.41% from the prior year.
• Common Equity was $30.2 million for Q4 2025 at Anbio Biotechnology, up from $27.5 million in the prior quarter.
• The five-year high for Common Equity was $30.2 million in Q4 2025, with the low at $14.8 million in Q4 2023.
• Average Common Equity over 3 years is $22.4 million, with a median of $22.4 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity increased 16.01% in 2024, then jumped 75.41% in 2025.
• Over 3 years, Common Equity stood at $14.8 million in 2023, then climbed by 16.01% to $17.2 million in 2024, then surged by 75.41% to $30.2 million in 2025.
• The last three Common Equity figures came in at $30.2 million (Q4 2025), $27.5 million (Q2 2025), and $17.2 million (Q4 2024), per Business Quant data.